Evidence map›Paper›PMID 33574685›Full record

ArticleInfection and drug resistance2021

Phenotypic and Genotypic Drug Susceptibility Assessment of

Maria Carolina Sisco, Marlei Gomes da Silva, Luciana Distasio de Carvalho, Carlos Eduardo Dias Campos, Paulo Cesar De Souza Caldas, Beatriz Lopez, Claudia Argüelles, Ana Carolina Carvalho, Jacobus de Waard, Philip Suffys and 1 more

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Maria Carolina SiscoLaboratório de Micobactérias, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Marlei Gomes da SilvaLaboratório de Micobactérias, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Luciana Distasio de CarvalhoLaboratório de Referência Nacional Para Tuberculose e Micobacterioses, Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Rio de Janeiro, Brazil.
Carlos Eduardo Dias CamposLaboratório de Referência Nacional Para Tuberculose e Micobacterioses, Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Rio de Janeiro, Brazil.
Paulo Cesar De Souza CaldasLaboratório de Referência Nacional Para Tuberculose e Micobacterioses, Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Rio de Janeiro, Brazil.
Beatriz LopezInstituto Nacional de Enfermedades Infecciosas, Buenos Aires, Argentina.ORCID 0000-0003-1212-7810
Claudia ArgüellesInstituto Nacional de Producción de Biológicos - ANLIS Carlos G Malbrán, Buenos Aires, Argentina.
Ana Carolina CarvalhoFaculdade de Farmácia, Universidade Federal do Rio de Janeiro, Campus Macaé, Rio de Janeiro, Brazil.ORCID 0000-0002-1163-3407
Jacobus de WaardDepartamento de Tuberculosis, Instituto Autónomo de Biomedicina Dr. Jacinto Convit, Caracas, Venezuela.ORCID 0000-0003-4118-1015
Philip SuffysLaboratório de Biologia Molecular Aplicada às Micobactérias, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.
Rafael Silva DuarteLaboratório de Micobactérias, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Universidade Federal do Rio de Janeiro · BREscola Nacional de Saúde Pública · BRAdministración Nacional de Laboratorios e Institutos de Salud · ARFundação Oswaldo Cruz · BRUniversidad de Las Américas · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose

methodsWe performed culture-based drug susceptibility testing of thirty one BCG strains isolated from patients in Brazil (n=5, 16%) and Argentina (n=26, 84%) using the broth micro-dilution method (phenotypic method). Final antibiotic concentrations for susceptibility testing ranged from 0.5 to 16 mg/L for amikacin, 0.3125 to 10 mg/L for ethambutol, 0.05 to 1.6 mg/L for isoniazid and 0.25 to 8 mg/L for rifampicin, streptomycin and ofloxacin. Additionally, we compared the results with genetic data obtained by whole genome sequencing.

resultsBy using the phenotypic method we detected one strain resistant to ethambutol, three strains resistant to rifampicin and one resistant to isoniazid. Additionally, two strains that were phenotypically resistant to both isoniazid and rifampicin carried mutations in the

conclusionThere is evidence of the emergence of BCG-resistant strains isolated from vaccine-related complications. We recommend drug susceptibility testing of the BCG strain causing the infection in order to prevent treatment failure.

Indexed as

BCGmycobacteriaresistancevaccine

Identifiers

PMID33574685
PMCPMC7872933
OpenAlexW3129113494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.